Key Insights

Highlights

Treatment Research

3 treatments under study, led by Dapagliflozin 5mg Tab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 4 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07891234Phase 4Not Yet RecruitingPrimary

Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance

Showing all 1 trials

Research Network

Common Treatments

  • Dapagliflozin 5mg Tab1
  • Dapagliflozin 10mg Tab1
  • Metfomin 500 Mg1

Active Sponsors

  • Ain Shams University1
  • Sherihan Aboelyazed Mohamed Khalil1

Activity Timeline